Merck is trading sharply higher today after releasing first-quarter 2026 financial results and updating its full-year 2026 outlook. The company lifted its full-year 2026 sales range to $65.8 billion to $67.0 billion, citing a roughly 1% positive foreign-exchange impact at mid-April 2026 rates and pointing to progress on approvals and clinical milestones.

For the first quarter of 2026, Merck reported a GAAP loss per share of $1.72 and a non-GAAP loss per share of $1.28. Despite the losses, the guidance raise and the company’s emphasis on pipeline and regulatory execution appear to be the key drivers of the bullish re-pricing in the shares.

Merck’s results arrive with investors focused on durability of its growth engine and the pace of diversification beyond its biggest products. A higher 2026 sales outlook can reduce near-term uncertainty around demand trends and pricing dynamics, while progress on approvals and clinical milestones can improve confidence in the longer-term pipeline contribution.

Investors will be watching management’s commentary on the earnings call for detail on what specifically drove the outlook increase, the cadence of launches and approvals, and how Merck expects to navigate near-term earnings volatility. Any additional clarity on capital allocation—particularly business development and pipeline investments—could influence whether the post-report rally holds.